Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight...
Focus:
-
Sarepta TherapeuticsLicensing Agreement$90M
-
BayerLicensing Agreement$100M
-
MerckMergers & Acquisitions$576M
-
CelgenePartnership$80M
-
VaximmPartnershipUndisclosed
-
LupinMergers & Acquisitions$526M
-
SandozMergers & Acquisitions$331M
-
NewpharmaPartnershipUndisclosed
-
Regeneron PharmaceuticalsPartnershipUndisclosed
-
BiogenLicensing Agreement$310M
-
Amneal PharmaceuticalsLicensing Agreement$18M
-
EisaiLicensing Agreement$330M
-
Takeda PharmaceuticalLicensing Agreement$660M
-
Janssen PharmaceuticalsPartnershipUndisclosed
-
AmgenMergers & Acquisitions$2.7BN
-
Dicerna PharmaceuticalsLicensing Agreement$1.6BN
-
Pandion TherapeuticsPartnership$795M
-
AstraZenecaLicensing Agreement$178M
-
Ziopharm OncologyPartnership$20M
-
ZentivaMergers & AcquisitionsUndisclosed
-
AbbVieLicensing AgreementUndisclosed
-
NovartisLicensing Agreement$80M
-
Takeda PharmaceuticalLicensing Agreement$420M
-
Zealand PharmaMergers & Acquisitions$80M
-
Bavarian NordicLicensing Agreement$336M
-
HealxCapital Raising$56M
-
Alexion PharmaceuticalsMergers & Acquisitions$930M
-
Daiichi SankyoLicensing Agreement$88.44M
-
AbbVieMergers & Acquisitions$63BN
-
IpsenLicensing Agreement$535M
-
![Bayer invests $100m for alliance with Dewpoint Therapeutics]()
Bayer to invest $100m for alliance with Dewpoint Therapeutics
-
![Merck acquires Calporta Therapeutics for $576m]()
Merck acquires Calporta Therapeutics for $576m
-
![Novartis’ Sandoz to acquire Aspen Japan]()
Novartis’ Sandoz to acquire Aspen Japan for $331m
-
![Regeneron and Vyriad to develop oncolytic virus therapies]()
Regeneron and Vyriad to develop oncolytic virus therapies
-
![Biogen signs commercialisation deal with Samsung Bioepis]()
Biogen signs commercialisation deal with Samsung Bioepis
-
![Takeda to divest select OTC products to STADA for $660m]()
Takeda to divest select OTC products to STADA for $660m
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics for $950m. Semma is an early-stage biotech that is developing stem cell therapies for type...
Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
Only eight months after the acceptance of its offer, Japanese pharma company Takeda completed its acquisition of international biotech Shire in January 2019.
US pharma industry sees a drop of 22.2% in deal activity in July 2019
The US pharma industry saw a drop of 22.2% in overall deal activity during July 2019, when compared with the last 12-month average, according to GlobalData's deals database.
Pharma industry deals in July 2019 total $4.57bn globally
Total pharma industry deals for July 2019 worth $4.57bn were announced globally, according to GlobalData's deals database.
Deals interview with Mike Preston of Cleary Gottlieb: Oncology is driving healthcare M&As
Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData’s deals database.
China’s pharma industry sees a drop of 28.1% in deal activity in Q2 2019
China's pharma industry saw a drop of 28.1% in overall deal activity during Q2 2019, when compared with the last four-quarter average, according to GlobalData's deals database.
North America’s pharma industry sees a drop of 10.3% in deal activity in Q2 2019
North America's pharma industry saw a drop of 10.3% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData's deals database.
Europe’s pharma industry sees a rise of 1.2% in deal activity in Q2 2019
Europe's pharma industry saw a rise of 1.2% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData's deals database.
Pharma industry M&A deals in Q2 2019 total $114.8bn globally
Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData's deals database.
Pharma industry venture financing deals in Q2 2019 total $2.72bn in US
Total pharma industry venture financing deals in Q2 2019 worth $2.72bn were announced in the US, according to GlobalData's deals database.
DEALS NEWS
Close
Close
Close
Go Top
